checkAd

    Hardman & Co  113  0 Kommentare Shield Therapeutics (STX): Cash management is key

    Für Sie zusammengefasst
    • Shield Therapeutics focuses on cash management
    • Company aims to be cashflow positive in 2H’25
    • No need for capital increase with extended financing options

    Hardman & Co Research
    Hardman & Co: Shield Therapeutics (STX): Cash management is key

    23-May-2024 / 07:15 GMT/BST
    The issuer is solely responsible for the content of this announcement.


    Hardman & Co Research on Shield Therapeutics (STX):

    Cash management is key

     

    Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield and its partner, Viatris, have increased physician awareness of the differentiating characteristics of Accrufer as an oral ID drug, in order to ramp up prescriptions (Rxs) and generate sales traction. Positive Rx momentum in 2022 and 2023, is expected to accelerate in 2024 and 2025 with the revised aim of becoming cashflow positive in 2H’25. This, coupled with extended financing options has obviated any requirement for a capital increase.

    Please click on the link below for the full report:

    https://hardmanandco.com/research/corporate-research/stx-cash-manageme ...

    If you are interested in meeting the company, you can register your interest by clicking on the above link.

    To contact us:

    Hardman & Co
    9 Bonhill Street

    London

    EC2A 4DJ

    www.hardmanandco.com

     

    Follow us on Twitter @HardmanandCo

    Contact:

    Dr Martin Hall



     

     

    mh@hardmanandco.com

     

    Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

    About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.



    Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
    The issuer is solely responsible for the content of this announcement.


    End of Announcement - EQS News Service

    1909175  23-May-2024 

    fncls.ssp?fn=show_t_gif&application_id=1909175&application_name=news&site_id=wallstreet~~~257e03b8-9cbc-48b8-b6a5-ec526abf7b8e 


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    Hardman & Co Shield Therapeutics (STX): Cash management is key Hardman & Co Research Hardman & Co: Shield Therapeutics (STX): Cash management is key 23-May-2024 / 07:15 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Shield Therapeutics (STX): Cash …